Business
GoodRx Announces Exclusive Low Cash Price for QSYMIA®, the Leading Branded Once-Daily Oral Weight Management Medication for Adults
First weight loss medication with an exclusive low cash price available on the GoodRx platform SANTA MONICA, Calif.--(BUSINESS WIRE)-- GoodRx (Nasdaq: GDRX),
About this update from Goodrx Holdings, Inc.
[{"type":"text","content":"\nFirst weight loss medication with an exclusive low cash price available on the GoodRx platform\n\n SANTA MONICA, Calif.--(BUSINESS WIRE)--\nGoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today that QSYMIA® (phentermine and topiramate extended-release capsules CIV) is available for a low cash price in more than 70,000 retail pharmacy locations nationwide exclusively via GoodRx. This initiative not only propels GoodRx’s momentum in weight loss solutions, but also broadens its portfolio in offering significant savings on brand-name medications, making obesity treatment more accessible and affordable for millions.\n\nAccording to the CDC, more than two in five U.S. adults have obesity, and untreated obesity increases the risk of type 2 diabetes, hypertension, heart disease, and mortality. While demand for weight-loss medications has soared in recent years, consumers often struggle to access them due to high costs and lack of insurance coverage. By making QSYMIA more accessible, GoodRx and Vivus are helping those struggling with weight and obesity find more affordable ways to access the treatments they need.\n\nNow, anyone with a valid prescription, regardless of insurance status, can use GoodRx to purchase a 30-day supply of QSYMIA at the exclusive cash price of $149. QSYMIA is designed to help patients manage hunger and reduce cravings throughout the day and, combined with a healthy diet and exercise, has been proven to help patients lose and maintain weight. Many individuals prefer oral medications over injectables, and the simplicity of taking a daily pill can make it easier to adhere to treatment regimens.\n\n“Obesity medications are life-changing for millions of Americans, but accessibility and affordability are often a barrier for many consumers,” said Dorothy Gemmell, Chief Commercial Officer at GoodRx. “Through this partnership, we’re making headway in getting these critical medications into the hands of those who need them and improving access to a medication that not only helps with weight loss, but is also tied to better outcomes for other costly chronic diseases.”\n\n“We are dedicated to expanding access to our critical medications that consumers rely on,” said John Amos, CEO at VIVUS. “Collaborating with GoodRx enables us to offer an affordable solution for individuals who have...